Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial

BACKGROUND: Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) has poor prognosis. Sorafenib/lenvatinib is recommended as the first-line therapy in these patients currently, with unsatisfactory response and survival benefit reported. Radiotherapy (RT) is increasingly ut...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yue, Qin, Tingting, Li, Shuang, Zhang, Tao, Xue, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479183/
https://www.ncbi.nlm.nih.gov/pubmed/32984021
http://dx.doi.org/10.3389/fonc.2020.01589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479183/
https://www.ncbi.nlm.nih.gov/pubmed/32984021
http://dx.doi.org/10.3389/fonc.2020.01589

Ejemplares similares